🚀 VC round data is live in beta, check it out!
Cerus Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cerus and similar public comparables like Coltene, IVF hartmann, TaiDoc Technology, CellaVision and more.
Cerus Overview
About Cerus
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Founded
1991
HQ
Employees
281
Website
Financials (LTM)
EV
$414M
Cerus Financials
Cerus reported last 12-month revenue of $239M and EBITDA of $10M.
In the same LTM period, Cerus generated $141M in gross profit, $10M in EBITDA, and had net loss of ($15M).
Revenue (LTM)
Cerus P&L
In the most recent fiscal year, Cerus reported revenue of $234M and EBITDA of $9M.
Cerus expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $239M | XXX | $234M | XXX | XXX | XXX |
| Gross Profit | $141M | XXX | $112M | XXX | XXX | XXX |
| Gross Margin | 59% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $10M | XXX | $9M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| EBIT Margin | (4%) | XXX | (4%) | XXX | XXX | XXX |
| Net Profit | ($15M) | XXX | ($16M) | XXX | XXX | XXX |
| Net Margin | (6%) | XXX | (7%) | XXX | XXX | XXX |
| Net Debt | — | — | $64M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cerus Stock Performance
Cerus has current market cap of $400M, and enterprise value of $414M.
Market Cap Evolution
Cerus' stock price is $2.08.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $414M | $400M | 0.0% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCerus Valuation Multiples
Cerus trades at 1.7x EV/Revenue multiple, and 39.5x EV/EBITDA.
EV / Revenue (LTM)
Cerus Financial Valuation Multiples
As of April 20, 2026, Cerus has market cap of $400M and EV of $414M.
Equity research analysts estimate Cerus' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cerus has a P/E ratio of (26.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $400M | XXX | $400M | XXX | XXX | XXX |
| EV (current) | $414M | XXX | $414M | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | 39.5x | XXX | 43.6x | XXX | XXX | XXX |
| EV/EBIT | (48.2x) | XXX | (47.7x) | XXX | XXX | XXX |
| EV/Gross Profit | 2.9x | XXX | 3.7x | XXX | XXX | XXX |
| P/E | (26.1x) | XXX | (25.6x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 373.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cerus Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cerus Margins & Growth Rates
Cerus' revenue in the last 12 month grew by 8%.
Cerus' revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.4M for the same period.
Cerus' rule of 40 is 27% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cerus' rule of X is 60% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cerus Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 42% | XXX | 35% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 27% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 60% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | 29% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cerus Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cerus | XXX | XXX | XXX | XXX | XXX | XXX |
| Coltene | XXX | XXX | XXX | XXX | XXX | XXX |
| IVF hartmann | XXX | XXX | XXX | XXX | XXX | XXX |
| TaiDoc Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| CellaVision | XXX | XXX | XXX | XXX | XXX | XXX |
| OrthoPediatrics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cerus M&A Activity
Cerus acquired XXX companies to date.
Last acquisition by Cerus was on XXXXXXXX, XXXXX. Cerus acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cerus
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCerus Investment Activity
Cerus invested in XXX companies to date.
Cerus made its latest investment on XXXXXXXX, XXXXX. Cerus invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cerus
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cerus
| When was Cerus founded? | Cerus was founded in 1991. |
| Where is Cerus headquartered? | Cerus is headquartered in United States. |
| How many employees does Cerus have? | As of today, Cerus has over 281 employees. |
| Who is the CEO of Cerus? | Cerus' CEO is William M. Greenman. |
| Is Cerus publicly listed? | Yes, Cerus is a public company listed on Nasdaq. |
| What is the stock symbol of Cerus? | Cerus trades under CERS ticker. |
| When did Cerus go public? | Cerus went public in 1997. |
| Who are competitors of Cerus? | Cerus main competitors are Coltene, IVF hartmann, TaiDoc Technology, CellaVision. |
| What is the current market cap of Cerus? | Cerus' current market cap is $400M. |
| What is the current revenue of Cerus? | Cerus' last 12 months revenue is $239M. |
| What is the current revenue growth of Cerus? | Cerus revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Cerus? | Current revenue multiple of Cerus is 1.7x. |
| Is Cerus profitable? | Yes, Cerus is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cerus? | Cerus' last 12 months EBITDA is $10M. |
| What is Cerus' EBITDA margin? | Cerus' last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Cerus? | Current EBITDA multiple of Cerus is 39.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.